Semaglutide vs. tirzepatide: separating clinical facts from TikTok hype

What's this video probably claiming?

Dr. Khin's TikTok, tagged with both #semaglutide and #tirzepatide, is almost certainly doing a comparison between the two drugs. That's the hottest topic in GLP-1 content right now, and for good reason. Creators in this space typically frame it as a head-to-head: which one causes more weight loss, which one has worse side effects, which one is worth the cost. Given the "knowledge sharing" framing and the doctor handle, this video likely presents clinical-sounding comparisons, possibly referencing trial data, possibly not. Some versions of this content are genuinely useful. Others cherry-pick numbers, flatten the nuance between weight-loss endpoints and metabolic endpoints, or imply that tirzepatide is simply a superior drug for everyone. Without the transcript, we can't confirm which camp this falls into, but the comparison format is predictable enough to fact-check the underlying claims now.

What does the science actually show?

The honest answer is that tirzepatide does outperform semaglutide on body weight reduction in the trials we have, but the comparison is messier than TikTok makes it look. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide 15mg achieving 22.5% mean body weight reduction over 72 weeks in adults with obesity. The STEP-1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg achieving 14.9% over 68 weeks. Those are different trials, different populations, different durations. The only head-to-head randomized data we have is SURPASS-2 (Frías et al., 2021, NEJM), which compared the two in type 2 diabetes patients specifically, not general obesity populations. Tirzepatide won on HbA1c and weight there too, but diabetes populations are not the same as the broader obesity population most social media content addresses. The drugs also work differently: semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist. That mechanism difference matters clinically.

Where does the social media noise diverge from clinical reality?

The biggest distortion in this content category is presenting the SURMOUNT vs. STEP numbers as a clean head-to-head when they are not. Cross-trial comparisons without randomization are hypothesis-generating at best. A second distortion is the implication that tirzepatide is simply better for everyone. Individual response varies substantially. In SURMOUNT-1, the standard deviation on weight loss was wide, meaning a meaningful portion of patients on tirzepatide 15mg lost far less than 22.5%. A third issue is side effect framing. Both drugs carry significant gastrointestinal side effect profiles. Nausea, vomiting, and constipation affect roughly 30-40% of users in trials. Tirzepatide's GIP component may modulate some GI effects, but the clinical difference in tolerability between the two agents is not as dramatic as social content implies. Finally, almost nobody on TikTok talks about the plateau problem: STEP-4 (Rubino et al., 2021, JAMA) showed that stopping semaglutide leads to substantial weight regain within a year, and there is no reason to think tirzepatide is different.

What should you actually know?

If you're weighing these two drugs, here is what the evidence actually supports. Tirzepatide appears to produce greater average weight loss than semaglutide at maximum approved doses, but this is based on separate trials, not a single head-to-head study in a weight-loss-only population. Both drugs require ongoing use to maintain results. Both carry real side effect risks that are not cosmetic inconveniences. Neither is a fix that works independently of diet and physical activity, despite how they're framed online. Dose titration matters enormously: most of the impressive weight loss numbers in trials come from the highest doses, and not every patient tolerates escalation to those doses. Cost and access are also real variables. Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide 15mg) both carry significant out-of-pocket costs when insurance doesn't cover them. Compounded versions exist but are not equivalent to FDA-approved formulations, and anyone suggesting otherwise is not giving you complete information.